



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

on May 7, 2002

By

*Diana M. Schaller*  
Diana M. Schaller

RECEIVED

MAY 20 2002

TECH CENTER 1603/2300

Attorney Docket No. 0217us210

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

J. Okkels, *et al.*

Application No.: 09/896,896

Filed: June 29, 2001

For: PEPTIDE EXTENDED  
GLYCOSYLATED POLYPEPTIDES

Examiner: Unassigned

Art Unit: 1633

STATEMENT ACCOMPANYING  
SEQUENCE LISTING

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir:

The enclosed paper (written) and CRF (diskette) copies of the Sequence Listing are provided in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply") and the Raw Sequence Listing Error Report ("Error Report") dated March 8, 2002 in the above referenced application. A copy of the Notice to Comply and the Error Report are also provided herein.

### REMARKS

The substitute Sequence Listing and CRF diskette are submitted in response to the Notice to Comply and the Raw Sequence Listing Error Report dated March 8, 2002.

The Examiner is hereby requested to delete the Sequence Listing on pages 84-146 of the specification as filed, and substitute therefor pages 1-50 of the Sequence Listing submitted concurrently herewith.

As directed in the Error Report, the Sequence Listing has been amended to include mandatory identifier field <160>. In addition, field <120> was corrected to show the correct title of the application, field <130> was corrected to show the current reference number of the application, fields <140> and <141> were added to list the application number and filing date, and multiple fields <150> and <151> were added to list priority application numbers and filing dates. These corrections to the Sequence Listing add no new matter to the specification.

SEQ ID NOs: 114 -123, which were inadvertently omitted from the Sequence Listing as originally filed, have been added in the Sequence Listing submitted concurrently herewith. Support for SEQ ID NOs: 114-121 is found, for example, on page 35, line 19 to page 36, line 2 of the specification as filed. Support for SEQ ID NOs:122 and 123 is found, for example, on page 83 lines 1-3 of the specification as filed. These additions to the Sequence Listing add no new matter to the specification.

The undersigned hereby states that the written Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed, and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted concurrently herewith.

### CONCLUSION

Applicants believe that no fee is required for this submission, since it is being submitted within the two-month deadline from the mailing date of the Notice to Comply. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 298-5452.

Respectfully submitted,



Joanne R. Petithory  
Reg. No. 42,995

Maxygen, Inc.  
515 Galveston Drive  
Redwood City, CA 94063  
Customer No. 30560

Phone: (650) 298-5452 (direct)  
(650) 298-5300 (main)  
Fax: (650) 298-5446